Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

143.48USD
30 Jan 2015
Change (% chg)

$-3.44 (-2.34%)
Prev Close
$146.92
Open
$144.43
Day's High
$145.50
Day's Low
$143.48
Volume
68,160
Avg. Vol
61,165
52-wk High
$150.63
52-wk Low
$124.36

BAYRY.PK

Chart for BAYRY.PK

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $119,857.70
Shares Outstanding(Mil.): 826.95
Dividend: 2.90
Yield (%): 2.02

Financials

  BAYRY.PK Industry Sector
P/E (TTM): 28.75 37.76 38.54
EPS (TTM): 4.99 -- --
ROI: 8.83 18.79 18.06
ROE: 18.18 19.44 18.83
Search Stocks

BRIEF-Bayer study to evaluate Xarelto in stroke patients

* Bayer forms collaboration with academic and governmental institutions for global phase III study to evaluate Xarelto

27 Jan 2015

Richter expects 40-50 mln euros annual sales of Bayer patch in 3-4 yrs

BUDAPEST, Jan 27 - Hungarian drugmaker Richter expects a contraceptive patch licensed from Bayer HealthCare to produce annual revenues worth 40-50 million euros in three to four years, Chief Executive Erik Bogsch told Reuters on Tuesday.

27 Jan 2015

BRIEF-Bayer forms collaboration for Rivaroxaban study

* Bayer news release: Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source Source text for Eikon: Further company coverage:

27 Jan 2015

BRIEF-Bayer receives recommendation in EU for new use of Aflibercept

* Says bayer receives recommendation for approval for new treatment option with aflibercept solution for injection in eu for the treatment of patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO) Further company coverage:

23 Jan 2015

BRIEF-AS Roma transfers Tin Jedvaj to Bayer 04 Leverkusen

* Reported on Tuesday that it has signed a contract with Bayer 04 Leverkusen for definitive sale of rights to the player Tin Jedvaj

21 Jan 2015

BRIEF-FDA approves Bayer's Gadavist for pediatric patients

* Says fda approves bayer's gadavist (gadobutrol) injection as first magnetic resonance contrast agent for pediatric patients less than 2 years of age Further company coverage: (Reporting By Thomas Atkins)

05 Jan 2015

IPO bankers earn a merry Christmas with a bumper year: data

LONDON/HONG KONG - Bankers responsible for floating companies and selling new shares into the market will enjoy a well-earned rest this Christmas after their busiest year since 2007, having notched up business worth almost $865 billion in the last 12 months.

22 Dec 2014

UPDATE 2-China officially approves imports of Bayer GMO soy variety

(Adds comments from Bayer's director of U.S. soybean operations)

19 Dec 2014

China officially approves imports of Bayer GMO soybean variety

CHICAGO - China has officially approved imports of a genetically modified Bayer CropScience soybean variety after seven years of review, the company said on Friday, raising expectations that approval notices will come soon for other grains.

19 Dec 2014

China officially approves imports of Bayer GMO soybean variety

CHICAGO, Dec 19 - China has officially approved imports of a genetically modified soybean variety developed by Bayer CropScience after seven years of review, the company said on Friday.

19 Dec 2014

Competitors

Earnings vs. Estimates

Search Stocks